• Login
    View Item 
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    •   Mak IR Home
    • College of Health Sciences (CHS)
    • School of Health Sciences (Health-Sciences)
    • School of Health Sciences (Health-Sciences) Collections
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda

    Thumbnail
    View/Open
    An Article (158.2Kb)
    Date
    2005
    Author
    Bakyaita, Nathan
    Dorsey, Grant
    Adoke, Yeka
    Banek, Kristin
    Staedke, Sarah G.
    Kamya, Moses R.
    Talisuna, Ambrose
    Kironde, Fred
    Nsobya, Sam
    Kilian, Albert
    Reingold, Arthur
    Rosenthal, Philip J.
    Wabwire-Mangen, Fred
    Metadata
    Show full item record
    Abstract
    The use of combinations of inexpensive drugs for the treatment of malaria in Africa has been proposed as an interim policy while awaiting the widespread availability of more effective regimens. We compared sulfadoxinepyrimethamine plus chloroquine or amodiaquine in three districts in Uganda. Patients aged 6 months or greater with uncomplicated falciparum malaria were enrolled and randomized to therapy. Safety, tolerability, and efficacy outcomes, adjusted by genotyping, were assessed over 28 days. Of 1,105 patients enrolled, 1,057 (96%) completed follow-up. For children less than 5 years old, the risk of clinical treatment failure adjusted by genotyping at the three sites ranged from 34% to 67% with chloroquine plus sulfadoxine-pyrimethamine and from 13% to 35% with amodiaquine plus sulfadoxine-pyrimethamine (risk differences 21–32%, P < 0.0001 at all sites). Serious adverse events were uncommon with both regimens. The risk of treatment failure with chloroquine plus sulfadoxine-pyrimethamine, the current standard in Uganda, was unacceptably high. Amodiaquine plus sulfadoxine-pyrimethamine was significantly more efficacious; however, existing levels of resistance raises concern about the useful therapeutic life-span of this regimen.
    URI
    http://hdl.handle.net/10570/1824
    Collections
    • School of Health Sciences (Health-Sciences) Collections

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of Mak IRCommunities & CollectionsTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy TypeThis CollectionTitlesAuthorsBy AdvisorBy Issue DateSubjectsBy Type

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    DSpace 5.8 copyright © Makerere University 
    Contact Us | Send Feedback
    Theme by 
    Atmire NV